Paige, a computational pathology startup targeting cancer, raises an additional $20M to close its Series B at $70M, bringing its total raised to $95M+
Context & Ripple Effects
This $20M extension tops up the $45M Series B Paige closed in late 2019, taking that round to $70M and total funding past $95M — an unusually large add-on for a startup still pre-clearance. The asset underwriting the raise dates to Paige's 2018 Series A, which secured access to Memorial Sloan Kettering's archive of 25 million pathology slides.
The follow-on reads as a bridge-and-validation move: six months later Paige had converted it into a $100M Series C led by Casdin Capital and Johnson & Johnson Innovation, and by September 2021 its prostate-cancer algorithm had won FDA clearance. Investors who extended the B were effectively buying earlier entry into what became a cleared diagnostic product.
First-order effects
- Paige gains extended runway between the Series B and Series C without resetting its valuation narrative, letting it keep building on the Sloan Kettering slide dataset while the larger round was assembled.
- The new money deepens existing backers' positions rather than introducing a lead, signaling insider conviction in the computational-pathology thesis at a time when clinical validation was still pending.
Second-order effects
- Casdin Capital's parallel lead of C2i Genomics' $100M Series B shows specialist healthcare investors consolidating positions across AI cancer diagnostics, pushing generalist funds toward later, pricier entries.
- Rival Proscia's later $50M raise for pathology digitization confirms that Paige's funding cadence forced the whole digital-pathology stack — software, scanners, algorithms — to compete for the same venture capital.
Third-order effects
- With the FDA clearance that followed, AI cancer diagnostics crossed from research tooling to regulated clinical products, making regulatory milestones — not model performance — the gating asset that determines fundraising power in this category.
The trend: Computational pathology is maturing from data-partnership startups into FDA-regulated diagnostics businesses, with specialist healthcare capital front-running each regulatory step.